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Abstract : Rhinitis frequently precedes asthma, and treating allergic rhinitis has benefi-
cial effects on asthma. suggesting upper airway disease is a risk factor for asthma.
The aim of the present study was to investigate the influence of allergic rhinitis on se-
rum IgE level. leukotriene generation by peripheral leukocytes, and bronchial
hyperresponsiveness (BHR) to methacholine in patients with atopic asthma. Seventy-one
asthmatic subjects (mean age, 59.5±12.5 years; 37 women, 34 men) were recruited,
and 48 asthmatics had allergic rhinitis and 23 asthmatics did not have allergic rhinitis.
The 10glO(Dmin) was significantly lower for those with allergic rhinitis than those with-
out allergic rhinitis (p<0.05), implying that those with allergic rhinitis developed BHR
to a greater degree than those without allergic rhinitis. LTC, generation from periph-
eral leukocytes was significantly greater for atopic asthmatics with allergic rhinitis than
those without allergic rhinitis (p<0.05). In contrast, the amount of LTB, produced
from peripheral leukocytes did not significantly differ between asthmatic patients with
and without allergic rhinitis. These results suggest that the presence of allergic rhinitis
enhances BHR by enhancing LTC, production, while the presence of allergic rhinitis
did not affect LTB, production in patients with atopic asthma.
Key words : asthma, allergic rhinitis. leukotriene generation. bronchial
hyperresponsiveness
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Introduction
The incidence of allergic diseases such as
allergic rhinitis and asthma is increasing to epi-
demic proportions (allergic rhinitis: 10-50% ;
and asthma: 5-15%), both in the developed
and the developing world, with a reduced qual-
ity of life of the patients, lower productivity and
increasing medical costs 1I. The increasing evi-
dence on the links between allergic rhinitis and
asthma comes from epidemiological,
immunological and clinical studies 2 ). Epidemiol-
ogically, up to 40% of patients with allergic
rhinitis also have asthma, and up to 80% of pa-
tients with asthma experience nasal symptoms.
Rhinitis frequently precedes asthma, and treat-
ing allergic rhinitis has beneficial effects on asth-
ma, suggesting upper airway disease is a risk
factor for asthma3 , ,) •
Both allergic rhinitis and asthma are inflam-
matory diseases, and their inflammatory mecha-
nisms are similar in that they are characterized
by an inflammatory infiltrate made up of eosino-
phils, T cells, and mast cells that release sev-
eral mediators including leukotrienes (LTs),
chemokines and cytokines, local and systemic
immunoglobulin (Ig) E synthesis. A typical
early' phase and late phase response are also
common to both rhinitis and asthma. LTs are
potent proinflammatory mediators that partici-
pate in the pathophysiological changes in the
airways of patients with asthma 5) •
In previous studies, we have shown that
LTc. production by leukocytes is associated
with IgE-mediated allergy and exacerbation of
asthma; that generation of LTB, is closely re-
lated to bronchial hyperresponsiveness (BRR)
in patients with asthma6 I ; and that cigarette
smoking enhances production of IgE antibodies,
BRR and generation of LTB, by leukocytes in
elderly asthmatics 7) •
The aim of the present study was to investigate
the influence of allergic rhinitis on serum IgE
level, leukotriene generation by peripheral leu-
kocytes, and BRR in patients with atopic asthma.
Subjects and Methods
SUBJECTS
Seventy-one asthmatic subjects (mean age,
59. 5±12. 5 years; 37 women, 34 men) were
recruited from Misasa Medical Center. Asthma
was diagnosed according to the definition pro-
posed by the American Thoracic Society8). All
subjects had specific IgE antibodies against in-
halant allergens. All subjects were life-long non-
smokers, and stable, with no changes in
asthma symptoms or medication for at least 1
month, except for the use of short-acting B2
agonists. Nine of the 71 patients were being ad-
ministered a long-term systemic glucocorticoid
regimen, and had been treated with
glucocorticoids for more than 2 years. No pa-
tients were treated with LT modulators or nasal
steroids. Allergic rhinitis .was diagnosed on the
basis of clinical history, symptom and the pres-
ence of specific IgE antibodies. Serum IgE was
measured using a radioimmunosorbent test
(RIST), and IgE antibodies specific to 12 com-
mon aeroallergens including house dust mites,
moulds, pollens and animal danders were meas-
ured using the Pharmacia CAP system
(Pharmacia Diagnostics AB, Uppsala, Sweden).
Informed consent was obtained from all sub-
jects, and the study protocol was approved by
the ethics committee of our institution.
BRONCHIAL RESPONSIVENESS
Bronchial responsiveness to methacholine was
measured using an Astograph (TCK6100, Chest
Co). Different concentrations of methacholine
(49, 98, 195, 390, 781, 1563, 3125, 6250 and
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12 500 fl g/ml) were prepared, and were used
for bronchial challenge according to the method
used by Chai et al. 9).
The increase in total respiratory resistance
(Rrs) after methacholine inhalation was meas-
ured using the oscillation technique. A cumula-
tive dose of methacholine that caused a signifi-
cant increase in Rrs was assessed as the mini-
mum dose (Dmin). The units for Dmin are
equivalent to 1 min of aerosol inhalation at 1 mg
/ mL during quiet tidal breathing. All medica-
tions were stopped 12 hours prior to examination.
LEUKOTRIENE (8" C,) GENERATION
The amount of leukotrienes, LTB. and LTC.,
generated by peripheral leukocytes was assessed
as described previously6.7 ,10,11). First, 5 rnl of
6% dextran (molecular weight, -200,000 kDa)
(Nacalai Tesque Inc., Kyoto, Japan) was added
to 20 mL of heparinized peripheral blood, and
the resultant mixture was incubated for 1 hour
at room temperature. The leukocyte-rich plasma
supematant was then removed and used. The
number of cells was adjusted to 5x10 6 cells/mL
in Tris CM buffer (30 mM Trisma [pH 7.7],
120 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L
CaClz , O. 5 mmol/L MgClz), and the cells
were then incubated with 1 mg of the calcium
ionophore A23187 (Sigma, St Louis, MO) for
15 minutes at 37°C. After a 4x volume of
prechilled ethanol (final, 80% ethanol) was
added, the mixture was centrifuged at 3000 rpm
for 30 minutes. A syringe filter (Toyo Roshi
Co, Tokyo, Japan) was used to draw off-the
supematant, and the filtrate was decompressed
and dried to a solid. Quantification of LTB. and
LTC. was performed using high-performance
liquid chromatography (HPLC) and ultraviolet
(DV) spectroscopy , following the method of
Lam et al. 1Z). Quantities of LTB. and LTC.
were expressed as nanograms per 5x10 6 cells.
PULMONARY FUNCTION TESTS
Pulmonary function tests were performed us-
ing a CHESfAC 33 system (Chest Co., Tokyo,
Japan). For all subjects, the following measure-
ments were made using the forced vital capacity
(FVC) maneuver: FVC, forced expiratory vol-
ume in 1 second (FEV1), FEV1/FVC, mean
forced expiratory flow during the middle half of
the FVC (FEF25-75). Measurements of FVC,
FEV!, and FEF25 -75 for each patient were ex-
pressed as a percentage of the predicted values13) •
STATISTICAL ANALYSIS
All statistical analyses were performed using
Stat View software (SAS Institute Inc., Cary,
(NC, USA). Results were expressed as mean
± SD. The differences between groups were
judged with the unpaired t test or the Mann-
Whitney U test for continuous data, and with
chi-square tests for categorical data. A p value
of <O. 05 was considered to indicate statistical
significance.
Results
The clinical characteristics of 48 asthmatics
with allergic rhinitis and 23 asthmatics without
allergic rhinitis are presented in Table 1. The
dosage of medication did not differ between the
asthmatic groups. There was no significant dif-
ference between those with and without allergic
rhinitis in patient age, %FVC, %FEV!, FEF25-75
or FEV!/FVC. The geometric mean of serum
IgE level was 299 IV/ rnl in those with allergic
rhinitis, and 183 IV/rnl in those without aller-
gic rhinitis. However, there was no significant
difference between the asthmatic groups.
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Table 1. Patient characteristics
AR(-) AR(+) Difference
Number of patients 23 48
FemalelMale 11/12 26/22 NS
Age (yrs) 62.0 ± 10.9 58.3 ± 13.2 NS
Serum IgE (ID/mn * 183 299(6-2250) • (20-2916) NS
%FVC(%) 102.5±22.2 102.5±16.3 NS
%FEVj (%) 90.4::1:23.9 90.6±22.6 NS
FEV,/FVC (%) 67.3±11.4 69.3±12.2 NS
%FEF25-75 (%) 64.3±33.2 6D.l±30.5 NS
Medication
Inhaled BDP
(mg/day) 365±344 483±675 NS
Systemic
NS
corticosteroids (n)
Data are presented as mean ± SD.
*: Values are geometric means of serum IgE levels, with range shown in
parentheses.
AR :=: allergic rhinitis; FVC = forced vital capacity; FEV I = forced expiratory
volume in one second; FEF25_15 = mean forced expiratory flow during the
middle half of the FVC; BDP = beclomethasone dipropionate.
Figure 1 shows the comparison of BRR to
methacholine between atopic asthmatics with
and without allergic rhinitis. The 10glO (Dmin)
was -0.172 ± O. 568 in asthmatics with allergic
rhinitis and O. 290±O. 540 in asthmatics without
allergic rhinitis. The 10glO (Dmin) was signifi-
cantly lower for those with allergic rhinitis than
those without allergic rhinitis (p< 0.05), imply-
ing that those with allergic rhinitis developed
BRR to a greater degree than those without al-
lergic rhinitis.
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Figure 1. Bronchial hyperresponsiveness to
methacholine in atopic asthmatic patients with and
without allergic rhinitis. AR = allergic rhinitis.
Figure 2 and 3 show the influence of allergic
rhinitis on the generation of LTB. and LTC.
from peripheral leukocytes in patients with
atopic asthma by stimulation with the calcium
ionophore A23187. The amount of LTB. gener-
ated by the leukocytes was 95.7 ± 23. 9 ng/
5xl0 6 cells in asthmatics with allergic rhinitis
and 88. 2±31. 2 ng/5xl0 6 cells in asthmatics
without allergic rhinitis. No significant differ-
ences were found between the asthmatic groups
(Figure 2). The amount of LTC. generated by
the leukocytes was 80. 5±58. 2 ng/5xl0 6 cells
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Figure 2. Leukotriene B. generation by peripheral
leukocytes in atopic asthmatic patients with and
without allergic rhinitis.
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Discussion
Figure 3.
Figure 3. Leukotriene C. generation by peripheral
leukocytes in atopic asthmatic patients with and
without allergic rhinitis.
in asthmatics with allergic rhinitis and 48.9±
38.3 ng/5xl0 6 cells in asthmatics without aller-
gic rhinitis. The leukocytes of atopic asthma pa-
tients with allergic asthma produced significantly
more LTC, than the leukocytes of those without
allergic rhinitis (p<0.05) (Figure 3).
recently rhinitis 17l • It is also well established
that nonspecific BHR to methacholine is more
frequent in rhinitic patients as compared to
nonrhinitic subjects, independently of the pres-
ence of atopy18-2il. In the present study, we ex-
amined how the presence of allergic rhinitis in-
fluences serum IgE level, BHR, and leukotriene
production by peripheral leukocytes stimulated
by calcium ionophore A23187 , which reflects
the pathogenesis of asthma, in patients with
atopic asthma.
In the present study, BHR and generation of
LTC, by peripheral leukocytes were significantly
greater for atopic asthmatics with allergic
rhinitis than those without allergic rhinitis. In
contrast, the amount of LTB, produced from
peripheral leukocytes did not significantly differ
between asthmatic patients with and without
allergic rhinitis. These results suggest that the
presence of allergic rhinitis enhances BHR by
enhancing LTC, production, while the presence
of allergic rhinitis did not affect LTB. produc-
tion in patients with atopic asthma.
Leukotrienes are lipid mediators generated by
metabolism of arachidonic acid. They fall into 2
classes: Cys-LTs such as LTC, , LTD, , LTE, ,
which induce bronchoconstriction, enhance BHR
and smooth muscle hypertrophy, cause mucus
hypersecretion and mucosal edema, and induce
influx of eosinophils into airway tissue ; and the
dihydroxy acids such as LTB" which are
neutrophil chemoattractants22}. The findings of
Fujimura et al. indicate that interleukin-8 in-
duces BHR and airway neutrophil accumulation in
guinea pigs in viV0 23}, and suggest that this
effect is partly mediated by the release of LTB,.
Factors mechanistically linking upper and
lower airway allergic inflammation include loss
of nasal protection secondary to rhinitis-induced
congestion and nasal-bronchial reflex2,,25}. Aller-
gen-specific IgE production is strongly
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Asthma and allergic rhinitis occur frequently,
are very often associated and both cause a high
rate of morbidity. A recent epidemiological
study of risk factors for rhinitis and asthma es-
tablished that although rhinitis was a risk factor
for the onset of asthma, asthma was not a risk
factor for the onset of rhinitis, which suggested
that in reality rhinitis precedes asthma"}. Cys-
LTs are iniportant mediators in the pathophy-
siology of both asthma and allergic rhinitis, re-
leased in bOth the early and late phase of the
allergic reaction, and in many ways underpin
the 'one airway' concept of upper and lower air-
way disease IS} • Leukotriene receptor antagonists
(LTRAs), which inhibit the actions of cys-LTs,
have proved to be effective and well tolerated
therapies in the treatment of asthma 16} and more
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correlated with both allergic rhinitis and asthma,
suggesting allergic immune responses are im-
portant in their etiology and pathogenesis25,26).
The inflammatory processes arise from inappro-
priate immune responses to otherwise innocuous
aeroallergens resulting in development of an al-
lergic immune, instead of a tolerant phenotype.
Several studies have emphasized the importance
of Th2-type T cells in the development and
propagation of this response 27, 28) • Active inflam-
matory conditions in the nasosinus may result in
BHR through the cholinergic nervous system in-
duced by the direct stimulation of receptors in
the nasosinus and/or indirect stimulation of re-
ceptors in the nasopharynx from inflammatory
cells or products of post-nasal discharge29). This
nasobronchial reflex may in turn influence the
pathophysiology of bronchial asthma, such as
bronchial muscle tone 30) •
In conclusion, the present results suggest
that BHR and LTC, generation by peripheral
leukocytes are influenced by co-existing allergic
rhinitis. However, the mechanism leading to
BHR is complex and remains unclear, and is in-
fluenced not only by airway remodeling3Il • Thus,
there is a need for further detailed clinical stud-
ies to elucidate the relation between asthma and
allergic rhinitis.
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アレルギー性鼻炎を合併したアトピー性嘱息患者
におけるロイコトリエン産生能と気道過敏性
光延文裕,保崎泰弘,芦田耕三,岩垣尚史,
藤井 誠,高田莫吾,清田全紀*,谷崎勝朗
岡山大学医学部･歯学部附属病院三朝医療センター,
内科,リハビリテーション科
アレルギ 鼻ー炎は気管支哨息のリスクファクター
の一つであると考えられている｡しばしば職息に
先行して発症し,その治療を行うことは職息の治
療に有用であることが報告されている｡我々は本
検討において,アトピー性瑞息71例(平均年齢59.5
±12.5歳,女性37例,男性34例)を対象としアレ
ルギー性鼻炎の有無によって2群に分類し,血清
IgE値,末梢白血球のロイコトリエン産生能,メ
44
tis:implicationsforsinusitisandas也ma.J
AlergyClinImmunol101:3571360,1998.
31.KipsJC,PauwelsRA.:血rwaywallremo-
deling:doesitoccurandwhatdoesitmean?
ClinExpAlergyll:1457-1466,1999.
サコリンに対する気道過敏性を測定し,2群間で
比較検討した｡対象症例中,48例はアレルギー鼻
炎を合併し,23例はアレルギー鼻炎を合併してい
なかった｡アレルギー性鼻炎非合併例に比較して
アレルギー性鼻炎合併例において,気道過敏性は
有意に克進していた (p<0.05)｡末梢血白血球
のLTC4産生能も同様に,アレルギー性鼻炎非合
併例に比較してアレルギー性鼻炎合併例において
有意に克進していた (p<0.05)｡しかし,末梢
血白血球のLTB4産生能は,両群間で有意の差を
認めなかった｡以上より,アレルギー性鼻炎の存
在が末梢血白血球のⅠ:TC4産生克進を介して,気
道過敏性の克進に関連している可能性が示唆され
た｡
キーワード:気管支嘱息,アレルギー性鼻炎,ロ
イコトリエン産性能,気道過敏性
